Open Beta
TREN
MetriLume
TREN

US marketsPMCB

SEC-sourced researchBeta

PMCB

PharmaCyte Biotech, Inc.

Company comparison ↗

Data passport

CIK
0001157075
Exchange
Nasdaq
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Sep 14, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: April 2025: 0.0000 USD; April 2026: 0.0000 USD0 USD0 USD0April 2025April 2026
PMCB · Exact amounts and source periods · USD
Period endRevenueFiling date
April 20250.0000Jul 29, 2026
April 20260.0000Jul 29, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
April 20260.0000-19,424,654.0000-5,152,914.000046,753,242.000011,772,424.0000Jul 29, 2026
April 20250.000030,656,050.0000-2,978,296.000055,168,353.00003,277,284.0000Jul 29, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$0April 2026Jul 29, 202610-K
Previous period revenueRevenues$0April 2025Jul 29, 202610-K
Net incomeNetIncomeLoss-$19.42MApril 2026Jul 29, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$5.15MApril 2026Jul 29, 202610-K
Total assetsAssets$46.75MApril 2026Jul 29, 202610-K
Total liabilitiesLiabilities$11.77MApril 2026Jul 29, 202610-K

New filings

Explore methodology ↗